Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 166

Results For "disease"

2060 News Found

Amgen and Arrakis collaborate for small molecule therapeutics
Biotech | January 12, 2022

Amgen and Arrakis collaborate for small molecule therapeutics

Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen


Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


Covaxin booster neutralises Omicron and Delta variants: Study
News | January 12, 2022

Covaxin booster neutralises Omicron and Delta variants: Study

The study will be published on the pre-print server, medRXiv, shortly


Prof. Jason Kovacic bags Agilent Thought Leader award
News | January 11, 2022

Prof. Jason Kovacic bags Agilent Thought Leader award

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
Biotech | January 11, 2022

Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer

First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC


Pfizer and Beam enter research collaboration for In Vivo base editing programme
Biotech | January 11, 2022

Pfizer and Beam enter research collaboration for In Vivo base editing programme

Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies


Immune Biosolutions lead immunotherapy product neutralises Covid-19
Biotech | January 11, 2022

Immune Biosolutions lead immunotherapy product neutralises Covid-19

In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract


Molnupiravir best option to treat Covid-19 now: Experts
News | January 11, 2022

Molnupiravir best option to treat Covid-19 now: Experts

Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry